We create the future of health.

Watch brand video

We create the future of health

Learn how

The Bio Convergence company

We can create human tissues and organs using cells from our own bodies, paving the way to make us our own organ donors, reducing organ rejection and solve the problem with lack of donors.

We can improve healing by developing new, better and individualized treatments, even faster than before.

We can save lives with faster and more accurate methods for drug discovery, while eliminating the unnecessary use of animal testing.

We can prevent outbreaks and proactively plan around new diseases with better diagnostics.

Bico by the numbers - Q2

Future. Forward. Fast

  • Net sales Q2 2021
    0 MUSD
  • Organic growth Q2 2021
    0 %
  • Employees
    0 +
  • Labs
    0 +
  • Publications
    0 +
  • Countries
    0 +

We are BICO

We consist of several subsidiaries divided into the business areas Bioprinting, Biosciences and Bioautomation. Together, we provide technology, products and services to create, understand and master biology.

Where life and technology becomes one

Bio Convergence

The art of combining the power of biology, engineering and computer science to extend the boundaries of what’s possible to give people better and healthier lives.

We see a future where robotics, artificial intelligence, advanced genomics and bioprinting come together to fundamentally shift the global healthcare industry.

Making the seemingly impossible, possible

Focusing on bioprinting, multiomics, cell line development and diagnostics, we enable researchers to grow cells in 3D environments, conduct high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical and cosmetic industries.

Industry-leading experts​

Our products are used in more than 2,000 laboratories including the world’s top 20 leading pharmaceutical companies, in more than 65 countries and have been cited in more than 1,850 publications.

Making the seemingly impossible, possible

Focusing on bioprinting, multiomics, cell line development and diagnostics, we enable researchers to grow cells in 3D environments, conduct high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical and cosmetic industries.

Industry-leading experts​

Our products are used in more than 2,000 laboratories including the world’s top 20 leading pharmaceutical companies, in more than 65 countries and have been cited in more than 9,000 publications.

Investor

Follow our financial story as we create the future of health.

Investor page

Q2 Report

Read our latest quarterly report.

Download

Earnings call

August 18, 08:00 (EST)/14:00 (CEST)

Presentation earnings call

Video on demand

press releases

September 15, 2021BICO has acquired HUREL micro liver technologies to offer the market's most comprehensive liver in vitro services
September 7, 2021BICO welcomes Erica Bell as Chief People Officer as company nears 1,000 employees globally
August 27, 2021BICO has acquired Advanced BioMatrix, an innovative company focused on 3D applications, to, together, ensure a market leading portfolio of bioinks and reagents
August 23, 2021DISPENDIX welcomes Petros Apostolopoulos as new CEO to strengthen position as leading liquid handling and lab automation company
August 18, 2021Introducing BICO: The Global Leader in the Bio Convergence Revolution
August 18, 2021RegulatoryInterim report January-June 2021: Increased net sales of 628% driven by M&A and organic growth of 95% and positive EBITDA in Q2.
August 13, 2021Change of name and short name (ticker) for shares in CELLINK AB (publ)
August 12, 2021The name change has been registered: CELLINK AB (publ) new name is BICO Group AB (publ)
August 12, 2021Invitation to earnings call for interim report January-June 2021
August 6, 2021RegulatoryBulletin from Extraordinary General Meeting in CELLINK AB (publ)
July 30, 2021RegulatoryCELLINK announces an increase in number of shares and votes
July 19, 2021CELLINK launches the S.NEST, a high-throughput microbioreactor with real-time monitoring to ensure maximum cell growth and streamlined workflows
July 7, 2021CELLINK has initiated the process of changing name to BICO
July 7, 2021RegulatoryNotice of Extraordinary General Meeting of CELLINK AB (publ)
July 6, 2021Visikol partners with MatTek to leverage their advanced cell culture models in its suite of drug discovery services
June 30, 2021CELLINK completes the acquisition of Discover Echo
June 30, 2021CELLINK has been granted its first patent of robotic systems for personalized and automated aesthetic medical procedures
June 30, 2021RegulatoryCELLINK announces an increase in number of shares and votes
June 29, 2021CELLINK has been granted a patent for "Cellulose Nanofibrillar Bioink for 3D Bioprinting for Cell Culturing, Tissue Engineering and Regenerative Medicine Applications" from European Patent Office
June 26, 2021RegulatoryCELLINK has entered into an agreement to acquire Discover Echo Inc., an innovative and revolutionary microscopy company
June 23, 2021CELLINKs EpiDerm ™ skin model has been approved by the OECD as a stand-alone in-vitro test method for phototoxicity
May 31, 2021CELLINK completes the acquisition of Nanoscribe
May 24, 2021CELLINK Bioprinting moves to Entré Kallebäck
May 20, 2021CELLINK has acquired Visikol, a contract research services company focused on advanced imaging, 3D cell culture assays and digital pathology
May 19, 2021RegulatoryCELLINK has entered into an agreement to acquire Nanoscribe, a market leading 3D bioprinting company based on Two-Photon Polymerization technology
May 12, 2021RegulatoryInterim report January-March 2021: High organic growth, strengthened gross margin, and strategic acquisitions
April 30, 2021RegulatoryCELLINK announces an increase in number of shares and votes
April 26, 2021RegulatoryBulletin from Annual General Meeting in CELLINK AB (publ)
April 14, 2021CELLINK receives the prestigious gold award for the BIO X6 and wins two design excellence awards for the C.WASH and UP.SIGHT at the iF Design Awards 2021.
April 6, 2021CELLINK and UPM Biomedicals has formed a collaboration for ground-breaking 3D bioprinting developments
March 31, 2021Invitation to CELLINKs digital Capital Markets Day on May 12, 2021 with focus on the bioconvergence agenda
March 31, 2021RegulatoryCELLINK announces an increase in number of shares and votes
March 26, 2021RegulatoryNotice of Annual General Meeting of CELLINK AB (publ)
March 23, 2021BIO X6 wins prestigious Red Dot Design Award for outstanding design quality
March 22, 2021CELLINK completes the acquisition of MatTek Corporation
March 17, 2021RegulatoryCELLINK publishes Annual Report 2019/2020
March 15, 2021CELLINK launches the BIO MDX Series , a scaled-up revolution in biomedical manufacturing
March 12, 2021RegulatoryCELLINK AB announces the completion of the offering of Senior Unsecured Convertible Bonds convertible into Class B shares and a Class B share issue in an overall amount of SEK 3.0 billion
March 11, 2021RegulatoryCellink AB announces an offering of Senior Unsecured Convertible Bonds convertible into Class B shares and a Class B share issue in an expected amount of SEK 2.75 billion
March 10, 2021Correction in CELLINK’s Swedish press release
March 10, 2021RegulatoryCELLINK has entered into an agreement to acquire MatTek, the global leader in in-vitro technology and alternative drug testing models
March 1, 2021CELLINK completes the acquisition of Ginolis Oy
February 25, 2021RegulatoryYear-end report 19/20: Continued strong organic growth, positive result and strategic investments for the future
February 19, 2021Invitation to CELLINK’s earnings call – Year-end Report 2019/2020
February 15, 2021RegulatoryCELLINK has entered into an agreement to acquire the advanced robotics and diagnostics automation company Ginolis
February 8, 2021CELLINK announce distribution agreement including new products for Single-Cell RNA Sequencing and NGS Library Preparation
January 28, 2021CELLINK announces third year extension of collaboration with a global biopharmaceutical company for drug discovery
January 25, 2021CELLINK launches UP.SIGHT, a rapid, all-in-one imager and single-cell dispenser that offers double assurance of clonality
January 19, 2021CELLINK to bring Livecyte high content live cell imager to a wider audience
December 17, 2020RegulatoryBulletin from the extraordinary general meeting in CELLINK AB (publ)
Read more

FINANCIAL REPORTS

Annual report 2019/2020
Annual report 2018/2019
Annual Report 2017/2018
Annual Report 2016/2017 (SWE)
Annual report 2016 (SWE)
Read More

Calendar

November 10, 2021Q3 report 2021
February 23, 2022Year-end report 2021
March 16, 2022Annual report 2021
Read more
Message from the CEO

Unleashing the power of Bio Convergence

Erik Gatenholm, CEO at BICO, decided to change the group company name to better reflect the strategic bio convergence agenda and emphasize that the company comprises several subsidiaries divided into three business areas. Now, the journey begins to build a world-famous brand.

"We have always challenged and developed the industry. We will continue to do this in a new context since the new name releases even better opportunities to communicate our offering, our plans going forward, and how we contribute to create the health of the future.

Erik Gatenholm, CEO, BICO
Message from the CEO

Unleashing the power of Bio Convergence

Erik Gatenholm, CEO at BICO, decided to change the group company name to better reflect the strategic bio convergence agenda and emphasize that the company comprises several subsidiaries divided into three business areas. Now, the journey begins to build a world-famous brand.

"We have always challenged and developed the industry. We will continue to do this in a new context since the new name releases even better opportunities to communicate our offering, our plans going forward, and how we contribute to create the health of the future.

Erik Gatenholm, CEO, BICO

Q&A

    • Why did you change your name to BICO?
    • Since 2016, we have built a world-leading Group that offers something unique - namely a revolution in Bio Convergence. This concept is guiding for us and therefore we have changed the name of the parent company from CELLINK to BICO. The new name reflects our business strategic agenda within Bio Convergence and emphasizes that we are a Group consisting of 11 subsidiaries divided into three strong business areas: Bioprinting, Biosciences and Bioautomation.
    • What does BICO mean?
    • It is an abbreviation for BIo COnvergence which means that we combine the forces of biology, engineering and computer science to expand the boundaries of what is possible - to give people a better and healthier life. We see a future where robotics, artificial intelligence, advanced genomics and bioprinting are brought together to, together, advance the global health industry.
    • What is BICO?
    • BICO is the parent company for the Group with Group-wide functions and with a focus on delivering on the agenda for Bio Convergence, identifying synergies, developing the offering and technologies and contributing to the development of the Group's subsidiaries. Together, the Group will have clear focus on continuing to develop the business. Organizationally, BICO is divided into three business areas: Bioprinting, Biosciences and Bioautomation. Each business area includes the Group companies: CELLINK Bioprinting, MatTek, Visikol and Nanoscribe (Bioprinting), Cytena, Cytena BPS, Dispendix and Discover Echo (Biosciences) and SCIENION, CELLENION and Ginolis (Bioautomation).
    • What happens to CELLINK?
    • CELLINK is and remains a world-leading brand in 3D bioprinting. CELLINK will be a wholly owned subsidiary of BICO and will continue its goal-oriented work with a focus on bioprinting of human organs and tissues. For more information about CELLINK's innovative product portfolio and offer in 3D bioprinting, please visit www.cellink.com
    • If I already have shares or options do I need to do something?
    • This is an administrative matter and shareholders do not need to take any action
    • What should I do if I want to buy shares in BICO?
    • You enter BICO instead of CLNK. The company’s ISIN code and order book ID are unchanged.
    • What should I do if I want to sell shares in BICO?
    • You enter BICO instead of CLNK when you choose to sell shares from your depository.
    • Where can I find the latest interim report?
    • The Q2 report is available under the Financial Statements tab at bico.com/investors. Click here to download it immediately.
    • Where can I find historical reports and presentations?
    • All financial reports, presentations and annual reports are available under the financial reports tab at bico.com/investors. Click here to visit the section.
    • I subscribe to press releases and reports from CELLINK do I have to fill in again for BICO?
    • No, all subscribers have been transferred, and you will continue to receive information from BICO instead of CELLINK. If you wish to subscribe to our press releases, reports and annual reports, click here to access the registration form.
    • Who can I reach out to if I have any questions?
    • You are always welcome to contact ir@bico.com. We are here for you and to answer your questions.

Join the revolution

Bring your values to do work that matters—not just to you, but to the world

Contact us

    • Investor relations

    • Isabelle Ljunggren, Head of Communications
    • Email: il@bico.com

    • Sales

    • Visit our subsidiaries' websites to explore our product offering.

Press room

Bico-LifeTech-images-1920x1080px-45
press-erik-gatenholm-bico
press-bico-logo
Bico_Logo_RGB_Horizontal
Bico-LifeTech-images-1920x1080px-24 kopiera
Bico-LifeTech-images-1920x1080px-30
Previous
Next
Download media package

Press Releases

Financial Reports

Calendar

September 15, 2021BICO has acquired HUREL micro liver technologies to offer the market's most comprehensive liver in vitro services
September 7, 2021BICO welcomes Erica Bell as Chief People Officer as company nears 1,000 employees globally
August 27, 2021BICO has acquired Advanced BioMatrix, an innovative company focused on 3D applications, to, together, ensure a market leading portfolio of bioinks and reagents
August 23, 2021DISPENDIX welcomes Petros Apostolopoulos as new CEO to strengthen position as leading liquid handling and lab automation company
August 18, 2021Introducing BICO: The Global Leader in the Bio Convergence Revolution
August 18, 2021RegulatoryInterim report January-June 2021: Increased net sales of 628% driven by M&A and organic growth of 95% and positive EBITDA in Q2.
August 13, 2021Change of name and short name (ticker) for shares in CELLINK AB (publ)
August 12, 2021The name change has been registered: CELLINK AB (publ) new name is BICO Group AB (publ)
August 12, 2021Invitation to earnings call for interim report January-June 2021
August 6, 2021RegulatoryBulletin from Extraordinary General Meeting in CELLINK AB (publ)
July 30, 2021RegulatoryCELLINK announces an increase in number of shares and votes
July 19, 2021CELLINK launches the S.NEST, a high-throughput microbioreactor with real-time monitoring to ensure maximum cell growth and streamlined workflows
July 7, 2021CELLINK has initiated the process of changing name to BICO
July 7, 2021RegulatoryNotice of Extraordinary General Meeting of CELLINK AB (publ)
July 6, 2021Visikol partners with MatTek to leverage their advanced cell culture models in its suite of drug discovery services
June 30, 2021CELLINK completes the acquisition of Discover Echo
June 30, 2021CELLINK has been granted its first patent of robotic systems for personalized and automated aesthetic medical procedures
June 30, 2021RegulatoryCELLINK announces an increase in number of shares and votes
June 29, 2021CELLINK has been granted a patent for "Cellulose Nanofibrillar Bioink for 3D Bioprinting for Cell Culturing, Tissue Engineering and Regenerative Medicine Applications" from European Patent Office
June 26, 2021RegulatoryCELLINK has entered into an agreement to acquire Discover Echo Inc., an innovative and revolutionary microscopy company
June 23, 2021CELLINKs EpiDerm ™ skin model has been approved by the OECD as a stand-alone in-vitro test method for phototoxicity
May 31, 2021CELLINK completes the acquisition of Nanoscribe
May 24, 2021CELLINK Bioprinting moves to Entré Kallebäck
May 20, 2021CELLINK has acquired Visikol, a contract research services company focused on advanced imaging, 3D cell culture assays and digital pathology
May 19, 2021RegulatoryCELLINK has entered into an agreement to acquire Nanoscribe, a market leading 3D bioprinting company based on Two-Photon Polymerization technology
May 12, 2021RegulatoryInterim report January-March 2021: High organic growth, strengthened gross margin, and strategic acquisitions
April 30, 2021RegulatoryCELLINK announces an increase in number of shares and votes
April 26, 2021RegulatoryBulletin from Annual General Meeting in CELLINK AB (publ)
April 14, 2021CELLINK receives the prestigious gold award for the BIO X6 and wins two design excellence awards for the C.WASH and UP.SIGHT at the iF Design Awards 2021.
April 6, 2021CELLINK and UPM Biomedicals has formed a collaboration for ground-breaking 3D bioprinting developments
March 31, 2021Invitation to CELLINKs digital Capital Markets Day on May 12, 2021 with focus on the bioconvergence agenda
March 31, 2021RegulatoryCELLINK announces an increase in number of shares and votes
March 26, 2021RegulatoryNotice of Annual General Meeting of CELLINK AB (publ)
March 23, 2021BIO X6 wins prestigious Red Dot Design Award for outstanding design quality
March 22, 2021CELLINK completes the acquisition of MatTek Corporation
March 17, 2021RegulatoryCELLINK publishes Annual Report 2019/2020
March 15, 2021CELLINK launches the BIO MDX Series , a scaled-up revolution in biomedical manufacturing
March 12, 2021RegulatoryCELLINK AB announces the completion of the offering of Senior Unsecured Convertible Bonds convertible into Class B shares and a Class B share issue in an overall amount of SEK 3.0 billion
March 11, 2021RegulatoryCellink AB announces an offering of Senior Unsecured Convertible Bonds convertible into Class B shares and a Class B share issue in an expected amount of SEK 2.75 billion
March 10, 2021Correction in CELLINK’s Swedish press release
March 10, 2021RegulatoryCELLINK has entered into an agreement to acquire MatTek, the global leader in in-vitro technology and alternative drug testing models
March 1, 2021CELLINK completes the acquisition of Ginolis Oy
February 25, 2021RegulatoryYear-end report 19/20: Continued strong organic growth, positive result and strategic investments for the future
February 19, 2021Invitation to CELLINK’s earnings call – Year-end Report 2019/2020
February 15, 2021RegulatoryCELLINK has entered into an agreement to acquire the advanced robotics and diagnostics automation company Ginolis
February 8, 2021CELLINK announce distribution agreement including new products for Single-Cell RNA Sequencing and NGS Library Preparation
January 28, 2021CELLINK announces third year extension of collaboration with a global biopharmaceutical company for drug discovery
January 25, 2021CELLINK launches UP.SIGHT, a rapid, all-in-one imager and single-cell dispenser that offers double assurance of clonality
January 19, 2021CELLINK to bring Livecyte high content live cell imager to a wider audience
December 17, 2020RegulatoryBulletin from the extraordinary general meeting in CELLINK AB (publ)
Read more
Annual report 2019/2020
Annual report 2018/2019
Annual Report 2017/2018
Annual Report 2016/2017 (SWE)
Annual report 2016 (SWE)
Read More
November 10, 2021Q3 report 2021
February 23, 2022Year-end report 2021
March 16, 2022Annual report 2021
Read more